DNA Stock Recent News
DNA LATEST HEADLINES
Eli Lilly's valuation is through the roof, but it's not just hot air. Ginkgo Bioworks could become a great long-term pickup.
Ginkgo Bioworks is a cell programming specialist that has partnered with many big companies. It is in a very early stage, but has a lot of promising opportunities in the long run.
Cathie Wood's focus on disruptive technologies could be a winning strategy over the long term. Ginkgo Bioworks and Recursion Pharmaceuticals are two of her more intriguing holdings in the biotech industry.
Stocks won't automatically become more expensive when we shift into a new year. But those that have struggled this year and have strong long-term outlooks could rebound at any point.
These companies are just getting started along the path of revenue growth. Their technologies -- gene editing and organism engineering -- help them stand out from the crowd.
Synthetic biology refers to using engineered organisms to produce products for multiple industries. Specifically, the pharmaceutical, biotechnology, and agriculture sectors are set to benefit most from synthetic biology.
The cell programming upstart is partnering with behemoths like Pfizer and Alphabet. The business remains unproven, incurring heavy losses over the past four quarters.
Ginkgo Bioworks' Q3 results were relatively poor due to the difficult macro environment and the winding down of its COVID testing business. While Ginkgo's Cell Engineering business has enormous potential, data indicates that this business is still nascent. Investors expecting significant downstream value will need to be patient. Progress amongst pharmaceutical and biotech customers is an important development but most of these programs are yet to be completed.
Ginkgo Bioworks is successfully scaling its customer base. It's also making some progress towards profitability.
Ginkgo Bioworks Holdings Inc. (NYSE:DNA ) Q3 2023 Results Conference Call November 8, 2023 5:30 PM ET Company Participants Megan LeDuc - Manager of Investor Relations Jason Kelly - Founder, CEO & Director Mark Dmytruk - Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Poon Mah - TD Cowen Derik Bruin - BofA Securities Michael Freeman - Raymond James E.V. Koslosky - Goldman Sachs Megan LeDuc Good evening.